Register for our free email digests:
Solvay SA
www.solvay.com
Latest From Solvay SA
CIR’s Silica/Silicates Review Could Be First Test Of Panel’s Revised Inhalation Assessment Approach
The Cosmetic Ingredient Review Expert Panel has been grappling with the question of just how vital particle-size data is to assessing the potential inhalation risks of ingredients used in cosmetic sprays and powders. Its pending review of silica/silicate ingredients could provide a look at the panel’s evolving approach in action, with particle size data for all ingredients requested from industry ASAP.
Impax Defeats FTC Pay-For-Delay Complaint, Helped By Status As Sole Marketer Of Generic Opana ER
FTC Chief Administrative Law Judge finds procompetitive benefit of Endo-Impax patent settlement agreement outweighs unjustified no-authorized generic provision.
Impax Defeats FTC Pay-For-Delay Complaint, Helped By Status As Sole Marketer Of Generic Opana ER
FTC Chief Administrative Law Judge finds procompetitive benefit of Endo-Impax patent settlement agreement outweighs unjustified no-authorized generic provision.
Will FTC Shakeup Impact Pharma?
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Benelux
-
Belgium
-
Belgium
-
Benelux
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Solvay SA
- Senior Management
-
Christian Jourquin, CEO
Bernard de Laguiche, CFO - Contact Info
-
Solvay SA
Phone: (32) 2 509 61 11
rue du Prince Albert 33
Brussels, B-1050
Belgium
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice